Vaccine manufacturer Serum Institute of India said on 29 September 2020 that it would get a further USD150m in funding from the Bill & Melinda Gates Foundation and the GAVI vaccines alliance to make an additional 100 million COVID-19 vaccine doses, Reuters news agency reported on Tuesday.
These additional doses are for India and other low-income and middle-income countries in 2021.
Reportedly, this collaboration builds upon an initial agreement signed in August 2020 by the company with the GAVI alliance and the Gates Foundation, with the total number of vaccine doses to be covered by the partnership amounting to 200 million.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses